Neurology Drug Articles & Analysis
12 news found
The Company believes its technologies will become widely adopted for use in the fields of regenerative medicine, oncology, neurology, and drug development, enabling the Company to build a new, global life science business franchise. ...
Food and Drug Administration (FDA) has granted its lead compound, ENA-001, Orphan Drug Designation for the treatment of Apnea of Prematurity (AoP). ...
The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD," including addiction. ...
CanaQuest Medical Corp CanaQuest Medical is an award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. ...
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. ...
“We are excited to partner with Total Brain to combine the power of their high-dimensional data with our drug prediction engine to open new doors for drug discovery specifically addressing neurological conditions – something that has never been explored this way before,” said Dr. ...
The CCL2/CCR2 pathway plays an important role in oncology, inflammatory, metabolic, and neurological disorders. Using its proprietary drug discovery technology, Orion successfully completed the development of OB-004 from target identification to lead optimization in only 6 months, a significant reduction in discovery time compared to industry averages. ...
Axial is advancing a pipeline of small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological disease pathology, progression, and symptoms. ...
Austin, TX, September 27, 2021 -- Veravas, Inc., an early-stage diagnostics company, has announced the development of its VeraPrep™ Antibody Detection Kit, a new development platform that provides scientists with a state-of-the-art research tool to easily and quickly develop new tests to multiplex detect and measure immunoglobulins against new and emerging pathogens as well as ...
CanaQuest has identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions. ...
The capital will primarily be used to support the ongoing clinical development program for ILB™ and IBSOLVMIR®, advancing the company’s position within the treatment of acute and degenerative neurological diseases and cell transplantation. “We are delighted to have secured this funding, which shows the confidence our shareholders have in our unique ...
“MODAG has developed an exciting approach to addressing MSA, an indication that has been significantly neglected in drug development,” said Jeff Putman of Massa Investment AG. “The team brings together a deep-rooted scientific understanding and clinical expertise of the disease area, as well as operational leadership experience. ...